Merck & Co. (MRK)
(Delayed Data from NYSE)
$98.05 USD
-1.47 (-1.48%)
Updated Dec 20, 2024 04:03 PM ET
After-Market: $98.22 +0.17 (0.17%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.05 USD
-1.47 (-1.48%)
Updated Dec 20, 2024 04:03 PM ET
After-Market: $98.22 +0.17 (0.17%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Zacks News
Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More
by Zacks Equity Research
FOLD and EDIT are in the spotlight following patent dispute settlement news and strategic updates, respectively.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Merck (MRK) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close.
The Zacks Analyst Blog Highlights Visa, Netflix, Merck and Hovnanian
by Zacks Equity Research
Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog.
Top Research Reports for Visa, Netflix & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), Netflix, Inc. (NFLX) and Merck & Co., Inc. (MRK), as well as a micro-cap stock Hovnanian Enterprises, Inc. (HOV).
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?
by Kinjel Shah
We believe you may hold MRK stock, as the company has one of the world's best-selling drugs in its portfolio that generates billions of dollars in revenues.
Gilead, MRK Report Data From Investigational Combination Study for HIV
by Zacks Equity Research
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Merck (MRK) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $111.53, representing a +1.68% change from its previous close.
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
by Zacks Equity Research
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $110.27, signifying a +1.61% move from its prior day's close.
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?
by Zacks Equity Research
While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.
Stock Market News for Oct 4, 2024
by Zacks Equity Research
U.S. stock markets closed lower on Thursday after a choppy session.
Merck (MRK) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Merck (MRK) concluded the recent trading session at $110.18, signifying a -1.7% move from its prior day's close.
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
by Kinjel Shah
JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.
MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study
by Zacks Equity Research
The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.
AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal
by Zacks Equity Research
AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.
Company News for Sep 24, 2024
by Zacks Equity Research
Companies in The News Are: TSLA, DPZ, INTC, APO, MRK
EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer
by Zacks Equity Research
If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.